Payment overview · 2025
General Payments
$247.59
12 reported records · 4 companies
Healthcare provider profile · identity verified
Christopher Babiuch, MD
Allopathic & Osteopathic Physicians|Family Medicine · BERWYN, IL · NPI 1063689107
Verified facts
What the public records show
CMS Open Payments records show Christopher Babiuch, MD received $247.59 in general payments during 2025 across 12 reported records.
Abbott Laboratories accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $101.23 | 40.9% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $63.14 | 25.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.81 | 19.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.41 | 13.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $247.59 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $101.23 | 5 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $63.14 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.41 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
184 | 58 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 687 | 219 |
| Lisinopril | Lisinopril | 347 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 111 |
| Losartan Potassium | Losartan Potassium | 292 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 262 | 88 |
| Omeprazole | Omeprazole | 227 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 73 |
| Metformin Hcl | Metformin Hcl | 187 | 59 |
| Jardiance | Empagliflozin | 184 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 64 |
| Carvedilol | Carvedilol | 173 | 57 |
| Metformin Hcl Er | Metformin Hcl | 173 | 60 |
| Gabapentin | Gabapentin | 167 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 63 |
| Trazodone Hcl | Trazodone Hcl | 148 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 39 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 129 | 129 |
| Furosemide | Furosemide | 127 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 35 |
| Bupropion Xl | Bupropion Hcl | 110 | 39 |
| Eliquis | Apixaban | 95 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 36 |
| Simvastatin | Simvastatin | 95 | 29 |
| Famotidine | Famotidine | 93 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 31 |
| Potassium Chloride | Potassium Chloride | 87 | 36 |
| Trulicity | Dulaglutide | 81 | 26 |
| Glimepiride | Glimepiride | 80 | 25 |
| Ozempic | Semaglutide | 76 | 19 |
| Sertraline Hcl | Sertraline Hcl | 75 | 29 |
| Allopurinol | Allopurinol | 74 | 27 |
| Finasteride | Finasteride | 73 | 22 |
| Mounjaro | Tirzepatide | 73 | 20 |
| Tramadol Hcl | Tramadol Hcl | 71 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 66 | 63 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 16 |
| Twinrix | Hepatitis A And B Vaccine/Pf | 62 | 36 |
| Warfarin Sodium | Warfarin Sodium | 61 | 14 |
| Chlorthalidone | Chlorthalidone | 58 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 17 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 56 | 56 |
| Typhim Vi | Typhoid Vi Polysacch Vaccine | 56 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 19 |
| Pregabalin | Pregabalin | 54 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 12 |
| Meloxicam | Meloxicam | 47 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | 20 |
| Valacyclovir | Valacyclovir Hcl | 45 | 11 |
| Atenolol | Atenolol | 44 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 16 |
| Mirtazapine | Mirtazapine | 42 | 12 |
| Spironolactone | Spironolactone | 42 | 19 |
| Synthroid | Levothyroxine Sodium | 41 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 12 |
| Januvia | Sitagliptin Phosphate | 39 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 16 |
| Xarelto | Rivaroxaban | 39 | 13 |
| Rybelsus | Semaglutide | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | 11 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Prednisone | Prednisone | 29 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | 13 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Yf-Vax | Yellow Fever Vaccine Live/Pf | 23 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 15 |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Ipol | Poliomyelitis Vaccine, Killed | 14 | 14 |
| Lorazepam | Lorazepam | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Heplisav-B | Hepatitis B Vaccine/Cpg1018/Pf | 13 | suppressed |
| Vaqta | Hepatitis A Virus Vaccine/Pf | 13 | 13 |
| Clonazepam | Clonazepam | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 11 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $247.59 · 12 records | Abbott Laboratories | FREESTYLE LIBRE 3, WATCHMAN Access System, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error